益气健脾抗癌法对胃癌脾虚本质的影响及抗肿瘤作用实验研究
|
摘要
目的：胃癌是一种严重影响人们生命健康的恶性肿瘤，全球每年新发胃癌100余万例，中国占42%，死亡约80万，中国占35%，中国是胃癌发病率和死亡率最高的国家之一，发病率和死亡率均是世界平均水平两倍多。对胃癌的诊断及治疗是医学界关注的重要内容。在临床实践中，我们发现胃癌患者大多有中医脾虚证的表现，有疲乏、无力、食欲不振、抵抗力差、消瘦等表现。这是由于胃癌本身可以影响脾的运化和胃的受纳功能，而脾虚本身也降低了机体的抗邪能力，不利于控制胃癌，脾虚证和胃癌之间互相影响。前期临床研究已经初步证明，在“益气健脾抗癌”原则下形成的方剂治疗胃癌、肠癌，具有抗癌、改善患者的症状、减轻放化疗毒性等作用。胃癌的脾虚本质理论正是对胃癌和脾虚紧密相连关系的反映。在临床实践中，益气健脾抗癌法在治疗胃癌中具有重要的地位，通过实验研究揭示胃癌的脾虚本质以及益气健脾抗癌中药的作用机理具有重要的理论与实际意义。本实验研究正是基于这种胃癌脾虚本质的理论，建立人胃癌SGC-7901移植瘤裸小鼠模型，采用益气健脾中药及益气健脾抗癌中药干预胃癌鼠模型，观察对脾虚相关指标：瘤鼠体重、食量、饮水量、胃残留率、肠推进率、生长抑素、脾脏系数、脾脏蛋白激酶C（PKC）的影响；对肿瘤相关指标：瘤重、瘤体细胞凋亡及瘤体表皮生长因子（EGF）、血管内皮生长因子（VEGF）表达的影响，揭示胃癌的脾虚本质，及益气健脾抗癌法的抗癌作用机理。
材料与方法：胃癌细胞株为人胃癌细胞株SGC-7901，实验动物为裸小鼠。药物：益气健脾中药组成：太子参、茯苓、白术、甘草、半夏、陈皮、木香、砂仁。抗癌中药组成：山慈菇、土茯苓、浙贝母、白花蛇舌草。建立人胃癌细胞SGC-7901裸鼠皮下移植瘤模型：首先将人胃癌SGC-7901细胞株体外培养，选择对数生长期的肿瘤细胞，在裸鼠腋下接种肿瘤细胞悬液0.1ml，接种15天后形成癌瘤。每个实验分为空白组、模型组、益气健脾组、益气健脾抗癌组，每组10只。空白组给予生理盐水、模型组给予生理盐水、益气健脾组给予益气健脾中药、益气健脾抗癌组给予益气健脾合用抗癌中药。各组均灌胃14天。第一部分实验是益气健脾抗癌法对胃癌小鼠消化吸收功能影响的实验研究，测定的指标为：小鼠体重变化、食量、饮水量、胃残留率、肠推进率，用放射免疫法测定小肠及血浆中生长抑素含量。第二部分实验为益气健脾抗癌法对胃癌小鼠脾脏PKC影响的实验研究，测定的指标为：脾脏系数、采用Western blot法测定脾脏PKC蛋白表达。第三部分实验为益气健脾抗癌法抑制胃癌小鼠肿瘤生长及对EGF、VEGF表达影响的实验研究，测定指标：瘤重、抑瘤率、采用TUNEL法测定瘤体细胞凋亡、采用Western-blot法测定瘤体EGF、VEGF表达。
结果：
1.体重增加量：空白组最多为5.99±0.24g，明显多于其它三组（p＜0.05），模型组体重增加最少为2.50±0.27g，而益气健脾组体重增加为4.21±0.35g，益气健脾抗癌组体重增加量为4.62±0.40g，均好于模型组（p＜0.05）；益气健脾组与益气健脾抗癌组对比则无统计学意义，但后者有好于前者的趋势。在食量与饮水量方面，表现出了与体重变化相同的结果，空白组最好，依次为益气健脾抗癌组、益气健脾组和模型组，其它三组均明显好于模型组。
2.胃残留率及小肠推进率：空白组胃内残留率为31.2±11.4%、小肠推进率为65.4±9.6%，在各组中为最好，表现为胃内残留率最小，小肠推进率最大，其它三组与之比较有明显差别（p＜0.05），其中益气健脾抗癌组与空白组差别最小。模型组的胃内残留率为48.3±12.6%、小肠推进率为44.8±11.3%，在各组中为最差，其它三组与之比较有明显差别（p＜0.05）。益气健脾组胃内残留率为39.7±11.2%、小肠推进率为56.3±10.4%,益气健脾抗癌组胃内残留率为35.5±10.7%、小肠推进率为60.1±10.2%，给药两组比较无统计学差异，但益气健脾抗癌组有好于益气健脾组的趋势。
3.生长抑素：生长抑素含量在空白组最低为，小肠和血浆含量分别为143±32ng/g及84±32ng/L；在模型组最高，分别为182±51ng/g、125±39ng/L；益气健脾组为177±46ng/g、110±42ng/L益气健脾抗癌组为160±42ng/g、102±38ng/L。各组和空白组比较有明显差异（p＜0.05）。给药两组和模型组比较有明显差异（p＜0.05）；益气健脾组与益气健脾抗癌组对比，后者表现出了好于前者的趋势，但无统计学意义。
4.脾脏系数：空白组最大为1.17±0.12%，模型组脾脏系数最小为0.71±0.24%，益气健脾组为0.94±0.18%，益气健脾抗癌组为1.06±0.27%。和空白组比较，模型组和益气健脾组均小于空白组，有统计学意义（p＜0.05）；益气健脾抗癌组和空白组比较，脾脏系数略小，但无统计学差异；与模型组对比，其它三组的脾脏系数均明显大于模型组，有统计学意义（p＜0.05）。
5.脾脏PKC表达：空白组最高为0.557±0.028，其它各组依次为益气健脾抗癌组0.509±0.010、益气健脾组0.442±0.017、模型组0.419±0.021。和空白组相比，模型组PKC表达降低最明显（P<0.01），益气健脾组及益气健脾抗癌组PKC表达也降低（P<0.01、P<0.05）；和模型组比较，益气健脾组和益气健脾抗癌组PKC表达高于模型组，且有明显统计学意义（P<0.01），其中益气健脾抗癌组最高，但仍低于空白对照组。
6.瘤重和抑瘤率：模型组、益气健脾组、益气健脾抗癌组瘤重为分别为3.82±0.73g、2.76±0.25g、2.44±0.37g，药物治疗两组的肿瘤生长明显小于模型组，分析有统计学意义（p＜0.05）；益气健脾抗癌组的瘤重小于益气健脾组，对比有统计学意义（p＜0.05）。抑瘤率方面，益气健脾组和益气健脾抗癌组分别为28%、36%，益气健脾抗癌组明显高于益气健脾组。
7.凋亡细胞数：模型组、益气健脾组、益气健脾抗癌组的凋亡细胞数分别为0.80±0.79、7.30±1.57、18.00±2.45个，给药两组多于模型组，结果有统计学意义（p＜0.01）。益气健脾组与益气健脾抗癌组对比，后者的凋亡细胞明显多于前者，二者差别有统计学意义（p＜0.01）。
8. EGF、VEGF表达：模型组中EGF、VEGF表达最高，益气健脾组表达较之略低，但无统计学意义；益气健脾抗癌组EGF、VEGF表达明显低于前两者，结果有统计学意义（p＜0.05）。
结论：
1.胃癌能影响脾的运化功能，应用益气健脾中药治疗后，脾的功能有一定程度的改善，可以加强胃排空和小肠推进，但益气健脾联合抗癌中药后的健脾作用更加明显。
2.胃癌能抑制脾脏本身的生长，并对脾脏中的PKC表达有抑制作用，应用益气健脾抗癌中药治疗后，这种抑制作用得到了减弱。
3.益气健脾抗癌中药与单用益气健脾中药相比，其对肿瘤的抑制作用更加明显，不仅具有抗癌作用，而且对肿瘤生长相关的两个重要因素EGF、VEGF的表达有明显的抑制作用。
4.胃癌能影响脾的功能，应用益气健脾抗癌中药治疗后，能达到健脾和抗癌双重治疗目的。因此，在临床治疗上，在应用益气健脾中药的同时，应该联合应用具有抗癌作用的中药，这种联合用药的原则体现了中医辨病与辨证治疗结合的治疗理念，值得进一步推广。
Purpose：Gastric cancer is a serious impact on people's lives and health ofmalignant tumor, around the world each year there were more than one millionnew cancer cases, China accounted for42%, killed about800thousands, Chinaaccounted for35%, China was one of countries with the highest morbidity andmortality of gastric cancer, incidence and mortality rate was more than two timesof the world average level. The diagnosis and treatment of gastric cancer wasthe important content of medical attention. In clinical treatment, we found thatmost gastric cancer patients had spleen-qi deficiency syndromes. They often hadthe symptoms of fatigue,weakness,loss of appetite, poor body resistance, weightloss and other clinical manifestations. Gastric cancer could affect theascending function of spleen and transport function of stomach. The spleendeficiency also reduced the body's resistance to disease. These aspects madeit difficult to control gastric cancer. The spleen deficiency and stomach cancerinfluence each other. Preliminary clinical studies have proved that theformation of "Yiqi Jianpi anticancer" principle had the effect of anti-cancerin the treatment of digestive system tumor. It can improve the symptoms, reducethe toxicity of chemotherapy. The theory of the spleen deficiency essence ofgastric cancer reflects this relationship. In clinical practice, Yiqi Jianpianticancer method plays an important role in the treatment of gastric cancer.Through the experimental study reveals the spleen deficiency essence of gastriccancer, the mechanisms of Yiqi Jianpi anticancer drugs has important theoreticaland practical significance. This study is based on the theory of the spleendeficiency essence of gastric cancer, establishing human gastric cancer SGC-7901model in nude mice. Treat the gastric cancer mouse model with the traditionalChinese medicine of Yiqi Jianpi and Yiqi Jianpi anti-cancer. Observe relevantindexes of spleen deficiency: mice weight, food intake, water intake, gastricresidual rate, intestinal propulsion, somatostatin, spleen coefficient, spleen protein kinase C (PKC) effect; the parameters related to tumor growth and tumorbody: epidermal growth factor (EGF), vascular endothelial growth factor (VEGF)expression of gastric cancer with deficiency of the spleen, revealing the spleendeficiency essence of gastric cancer and the mechanism of Yiqi Jianpi anti-cancerdrugs.
Material and method：
1. Choose human gastric carcinoma cell line SGC-7901, the experimental animalwas nude mice.
2. Drugs: Chinese medicine Yiqi Jianpi include: Radix Pseudostellariae, Poria,Atractylodes, licorice root, pinellia, dried orange peel, Amomum villosum,costas. Anticancer medicine composition include: tulip, tuckahoe, ZhejiangFritillaria, Oldenlandia diffusa.
3.To establish the model of human gastric cancer cell SGC-7901xenografts innude mice: the culture of human gastric cancer cell line SGC-7901in vitro,selection of tumor cells in logarithmic growth phase, nude mice inoculated with0.1ml tumor cells, the tumor will formate15days after inoculation.
4. Administration: experiment animals were divided into blank group, model group,Yiqi Jianpi group, Yiqi Jianpi cancer group. There were10rats in each group.The blank control group were treated with normal saline; model group were givensaline, Yiqi Jianpi group were given Yiqi Jianpimedicine; Yiqi Jianpi anticancergroup were given Yiqi Jianpi anticancer medicine. The blank group and model group weretreated with normal saline for14days. The drug groups were given correspondingmedicine for14days.
5. Indicators: The first part of the experiment was the experimental study YiqiJianpi anticancer effects on gastric cancer in mice by absorption digestion,the indexs: nude mice weight, food intake and water intake, gastric residualrate, intestinal propulsion rate, determination of the content of somatostatinin small intestine and in plasma by radioimmunoassay. The second study was theeffects of Yiqi Jianpi anticancer on the PKC of mice spleen, the indexes:expression of PKC protein was detected by Western blot method.The third part of the experiment was observation on gastric cancer tumor growth in mice andtumor EGF, VEGF expression, the index: tumor weight, inhibition rate of tumor,and tumor cell apoptosis was determined by TUNEL method, the expression of thetumor EGF, VEGF were determined by Western-blot method.
Results：
1．Amounts of weight gain: blank group was5.99±0.24g, significantly more thanthe other three groups (P <0.05), model group was2.50±0.27g, and Yiqi Jianpigroup was4.21±0.35g, Yiqi Jianpi anticancer group was4.62±0.40g, the otherthree groups were better than the model group (P <0.05). No statisticalsignificance of Yiqi Jianpi group and Yiqi Jianpi anticancer group was observed,but the latter was better than the former trend. In the aspect of food intakeand water intake, showed the same results with the weight change, blank groupwas the best, followed by Yiqi Jianpi anticancer group, Yiqi Jianpi group andmodel group, the other three groups were better than model group.
2．gastric residual rate and intestinal propulsive rate: in the blank group,the gastric residual rate was31.2±11.4%and small intestinal propulsion ratewas65.4±9.6%, was the best in all groups, had the minimum gastric residualrate and the maximum small intestinal propulsion rate, there were significantdifference (P <0.05) compared with the other three groups, the difference ofYiqi Jianpi anticancer group and the blank group was minimum. In model group,the gastric residual rate was48.3±12.6%and small intestinal propulsion ratewas44.8±11.3%, was the worst in all groups, there were significant difference(P <0.05) compared with the other three groups. Yiqi Jianpi group, gastricresidual rate was39.7±11.2%, small intestinal propulsion rate was56.3±10.4%,Yiqi Jianpi anticancer group, gastric residual rate was35.5±10.7%, smallintestinal propulsion rate was60.1±10.2%, there was no difference between thetwo groups, but the Yiqi Jianpi anticancer group had a better trend to Yiqi Jianpigroup.
3. Somatostatin. the amounts of somatostatin were lowest in the blank group,the small intestine and the plasma levels were143±32ng/g and84±32ng/L. the amounts of somatostatin were the highest In the model group, were182±51ng/gand125±39ng/L; In Yiqi Jianpi group were177±46ng/g and110±42ng/L. In YiqiJianpi anticancer group were160±42ng/g and102±38ng/L. There were obviousdifferences between groups and the blank group (P <0.05). compared with themodel there was significant difference between Yiqi Jianpi group and the modelgroup (P <0.05), there was significant difference between Yiqi Jianpi anticancergroup and the model group also(P <0.05). Compared with the Yiqi Jianpi group,the Yiqi Jianpi anticancer group showed a good trend, but without statisticalsignificance.
4. Spleen coefficient: the spleen coefficient in blank group was1.17±0.12%,model group was0.71±0.24%, Yiqi Jianpi group was0.94±0.18%, Yiqi Jianpianticancer group was1.06±0.27%. Compared with the blank group, model groupand Yiqi Jianpi group were less than the blank group, there were statisticallysignificant (P <0.05); the Yiqi Jianpi anticancer group were little less thanthe blank group, but there was no significant difference between the two groups.Compared with the model group, spleen coefficient of the other three groups weresignificantly higher than model group, there were statistical significance (P<0.05).
5. The expression of PKC in the spleen: blank group was0.557±0.028, other groupswere Yiqi Jianpi anticancer group0.509±0.010, Yiqi Jianpi group0.442±0.017,model group0.419±0.021. Compared with the blank group, in the model group,the expression of PKC decreased most significantly (P<0.01), In Jianpi Yiqi groupand Yiqi Jianpi anticancer group, the expression of PKC also decreased (P<0.01,P<0.05). Compared with the model group, the expression of PKC were higher inJianpi Yiqi group and Yiqi Jianpi anticancer group,there were statisticalsignificance (P<0.01), the expression of PKC of Yiqi Jianpi anticancer groupwas highest in the three groups, but still lower than the blank group.
6.tumor weight and inhibition rate of tumor: the tumor weight of model group,Yiqi Jianpi group and Yiqi Jianpi anticancer group were3.82±0.73g,2.76±0.25gand2.44±0.37g, the tumor growth of the two groups were less than that in model group, there were statistical significance (P <0.05); the tumor weight of YiqiJianpi anticancer group was less than Yiqi Jianpi group, there was statisticallysignificant (P <0.05). The tumor inhibition rate of Yiqi Jianpi group amd YiqiJianpi anticancer group were28%,36%, there was obvious statisticalsignificance.
7. The number of apoptotic cells: the number of apoptotic cells of model group,Yiqi Jianpi group and Yiqi Jianpi anticancer group were0.80±0.79,7.30±1.57and18±2.45, Compared with the model group, the Yiqi Jianpi group and the YiqiJianpi anticancer group were higher, there were statistically significant (P<0.01). Compared with the Yiqi Jianpi group, the number of apoptotic cells ofthe Yiqi Jianpi anticancer group, was significantly more than the former, therewere statistically significant difference (P <0.01).
8. The expression of EGF, VEGF: model group, the expression of EGF, VEGF of modelwere the highest, the expression of Yiqi Jianpi groups were lower than the modelgroup, but there were no statistically significant; the expression of EGF, VEGFof Yiqi Jianpi anticancer group were significantly lower than that of the formertwo, there were statistically significant (P <0.05).
Conclusion：
1. Gastric cancer can affect the metabolic function of the spleen, the Yiqi JianpiChinese medicine can improve the spleen function, can strengthen gastricemptying and small intestinal propulsion, when the Yiqi Jianpi Chinese medicinewere used with the anticancer Chinese medicine together, the improve effect canbe more obvious.
2. Gastric cancer can inhibit the growth of spleen, inhibit the expression of spleenPKC, application of Yiqi Jianpi anticancer treatment, this inhibitory effectwas weakened.
3. Yiqi Jianpi anticancer treatment compared with the single Yiqi Jianpitreatment, the inhibitory effect on the tumor is more obvious, not only hadanticancer effects, but also can inhibit the expression of the EGF and VEGF,these were important genes related to tumor growth.
4. Gastric cancer can affect the function of the spleen, the application of YiqiJianpi anticancer treatment can achieve the dual goal of strengthening the spleenfunction and anticancer. Therefore, in clinical treatment, in the applicationof Yiqi Jianpi medicine, at the same time, the anticancer medicine should becombined, this combination principle embodies the combination of disease andsyndrome differentiation and treatment of TCM treatment philosophy, worthy offurther promotion.
材料与方法：胃癌细胞株为人胃癌细胞株SGC-7901，实验动物为裸小鼠。药物：益气健脾中药组成：太子参、茯苓、白术、甘草、半夏、陈皮、木香、砂仁。抗癌中药组成：山慈菇、土茯苓、浙贝母、白花蛇舌草。建立人胃癌细胞SGC-7901裸鼠皮下移植瘤模型：首先将人胃癌SGC-7901细胞株体外培养，选择对数生长期的肿瘤细胞，在裸鼠腋下接种肿瘤细胞悬液0.1ml，接种15天后形成癌瘤。每个实验分为空白组、模型组、益气健脾组、益气健脾抗癌组，每组10只。空白组给予生理盐水、模型组给予生理盐水、益气健脾组给予益气健脾中药、益气健脾抗癌组给予益气健脾合用抗癌中药。各组均灌胃14天。第一部分实验是益气健脾抗癌法对胃癌小鼠消化吸收功能影响的实验研究，测定的指标为：小鼠体重变化、食量、饮水量、胃残留率、肠推进率，用放射免疫法测定小肠及血浆中生长抑素含量。第二部分实验为益气健脾抗癌法对胃癌小鼠脾脏PKC影响的实验研究，测定的指标为：脾脏系数、采用Western blot法测定脾脏PKC蛋白表达。第三部分实验为益气健脾抗癌法抑制胃癌小鼠肿瘤生长及对EGF、VEGF表达影响的实验研究，测定指标：瘤重、抑瘤率、采用TUNEL法测定瘤体细胞凋亡、采用Western-blot法测定瘤体EGF、VEGF表达。
结果：
1.体重增加量：空白组最多为5.99±0.24g，明显多于其它三组（p＜0.05），模型组体重增加最少为2.50±0.27g，而益气健脾组体重增加为4.21±0.35g，益气健脾抗癌组体重增加量为4.62±0.40g，均好于模型组（p＜0.05）；益气健脾组与益气健脾抗癌组对比则无统计学意义，但后者有好于前者的趋势。在食量与饮水量方面，表现出了与体重变化相同的结果，空白组最好，依次为益气健脾抗癌组、益气健脾组和模型组，其它三组均明显好于模型组。
2.胃残留率及小肠推进率：空白组胃内残留率为31.2±11.4%、小肠推进率为65.4±9.6%，在各组中为最好，表现为胃内残留率最小，小肠推进率最大，其它三组与之比较有明显差别（p＜0.05），其中益气健脾抗癌组与空白组差别最小。模型组的胃内残留率为48.3±12.6%、小肠推进率为44.8±11.3%，在各组中为最差，其它三组与之比较有明显差别（p＜0.05）。益气健脾组胃内残留率为39.7±11.2%、小肠推进率为56.3±10.4%,益气健脾抗癌组胃内残留率为35.5±10.7%、小肠推进率为60.1±10.2%，给药两组比较无统计学差异，但益气健脾抗癌组有好于益气健脾组的趋势。
3.生长抑素：生长抑素含量在空白组最低为，小肠和血浆含量分别为143±32ng/g及84±32ng/L；在模型组最高，分别为182±51ng/g、125±39ng/L；益气健脾组为177±46ng/g、110±42ng/L益气健脾抗癌组为160±42ng/g、102±38ng/L。各组和空白组比较有明显差异（p＜0.05）。给药两组和模型组比较有明显差异（p＜0.05）；益气健脾组与益气健脾抗癌组对比，后者表现出了好于前者的趋势，但无统计学意义。
4.脾脏系数：空白组最大为1.17±0.12%，模型组脾脏系数最小为0.71±0.24%，益气健脾组为0.94±0.18%，益气健脾抗癌组为1.06±0.27%。和空白组比较，模型组和益气健脾组均小于空白组，有统计学意义（p＜0.05）；益气健脾抗癌组和空白组比较，脾脏系数略小，但无统计学差异；与模型组对比，其它三组的脾脏系数均明显大于模型组，有统计学意义（p＜0.05）。
5.脾脏PKC表达：空白组最高为0.557±0.028，其它各组依次为益气健脾抗癌组0.509±0.010、益气健脾组0.442±0.017、模型组0.419±0.021。和空白组相比，模型组PKC表达降低最明显（P<0.01），益气健脾组及益气健脾抗癌组PKC表达也降低（P<0.01、P<0.05）；和模型组比较，益气健脾组和益气健脾抗癌组PKC表达高于模型组，且有明显统计学意义（P<0.01），其中益气健脾抗癌组最高，但仍低于空白对照组。
6.瘤重和抑瘤率：模型组、益气健脾组、益气健脾抗癌组瘤重为分别为3.82±0.73g、2.76±0.25g、2.44±0.37g，药物治疗两组的肿瘤生长明显小于模型组，分析有统计学意义（p＜0.05）；益气健脾抗癌组的瘤重小于益气健脾组，对比有统计学意义（p＜0.05）。抑瘤率方面，益气健脾组和益气健脾抗癌组分别为28%、36%，益气健脾抗癌组明显高于益气健脾组。
7.凋亡细胞数：模型组、益气健脾组、益气健脾抗癌组的凋亡细胞数分别为0.80±0.79、7.30±1.57、18.00±2.45个，给药两组多于模型组，结果有统计学意义（p＜0.01）。益气健脾组与益气健脾抗癌组对比，后者的凋亡细胞明显多于前者，二者差别有统计学意义（p＜0.01）。
8. EGF、VEGF表达：模型组中EGF、VEGF表达最高，益气健脾组表达较之略低，但无统计学意义；益气健脾抗癌组EGF、VEGF表达明显低于前两者，结果有统计学意义（p＜0.05）。
结论：
1.胃癌能影响脾的运化功能，应用益气健脾中药治疗后，脾的功能有一定程度的改善，可以加强胃排空和小肠推进，但益气健脾联合抗癌中药后的健脾作用更加明显。
2.胃癌能抑制脾脏本身的生长，并对脾脏中的PKC表达有抑制作用，应用益气健脾抗癌中药治疗后，这种抑制作用得到了减弱。
3.益气健脾抗癌中药与单用益气健脾中药相比，其对肿瘤的抑制作用更加明显，不仅具有抗癌作用，而且对肿瘤生长相关的两个重要因素EGF、VEGF的表达有明显的抑制作用。
4.胃癌能影响脾的功能，应用益气健脾抗癌中药治疗后，能达到健脾和抗癌双重治疗目的。因此，在临床治疗上，在应用益气健脾中药的同时，应该联合应用具有抗癌作用的中药，这种联合用药的原则体现了中医辨病与辨证治疗结合的治疗理念，值得进一步推广。
Purpose：Gastric cancer is a serious impact on people's lives and health ofmalignant tumor, around the world each year there were more than one millionnew cancer cases, China accounted for42%, killed about800thousands, Chinaaccounted for35%, China was one of countries with the highest morbidity andmortality of gastric cancer, incidence and mortality rate was more than two timesof the world average level. The diagnosis and treatment of gastric cancer wasthe important content of medical attention. In clinical treatment, we found thatmost gastric cancer patients had spleen-qi deficiency syndromes. They often hadthe symptoms of fatigue,weakness,loss of appetite, poor body resistance, weightloss and other clinical manifestations. Gastric cancer could affect theascending function of spleen and transport function of stomach. The spleendeficiency also reduced the body's resistance to disease. These aspects madeit difficult to control gastric cancer. The spleen deficiency and stomach cancerinfluence each other. Preliminary clinical studies have proved that theformation of "Yiqi Jianpi anticancer" principle had the effect of anti-cancerin the treatment of digestive system tumor. It can improve the symptoms, reducethe toxicity of chemotherapy. The theory of the spleen deficiency essence ofgastric cancer reflects this relationship. In clinical practice, Yiqi Jianpianticancer method plays an important role in the treatment of gastric cancer.Through the experimental study reveals the spleen deficiency essence of gastriccancer, the mechanisms of Yiqi Jianpi anticancer drugs has important theoreticaland practical significance. This study is based on the theory of the spleendeficiency essence of gastric cancer, establishing human gastric cancer SGC-7901model in nude mice. Treat the gastric cancer mouse model with the traditionalChinese medicine of Yiqi Jianpi and Yiqi Jianpi anti-cancer. Observe relevantindexes of spleen deficiency: mice weight, food intake, water intake, gastricresidual rate, intestinal propulsion, somatostatin, spleen coefficient, spleen protein kinase C (PKC) effect; the parameters related to tumor growth and tumorbody: epidermal growth factor (EGF), vascular endothelial growth factor (VEGF)expression of gastric cancer with deficiency of the spleen, revealing the spleendeficiency essence of gastric cancer and the mechanism of Yiqi Jianpi anti-cancerdrugs.
Material and method：
1. Choose human gastric carcinoma cell line SGC-7901, the experimental animalwas nude mice.
2. Drugs: Chinese medicine Yiqi Jianpi include: Radix Pseudostellariae, Poria,Atractylodes, licorice root, pinellia, dried orange peel, Amomum villosum,costas. Anticancer medicine composition include: tulip, tuckahoe, ZhejiangFritillaria, Oldenlandia diffusa.
3.To establish the model of human gastric cancer cell SGC-7901xenografts innude mice: the culture of human gastric cancer cell line SGC-7901in vitro,selection of tumor cells in logarithmic growth phase, nude mice inoculated with0.1ml tumor cells, the tumor will formate15days after inoculation.
4. Administration: experiment animals were divided into blank group, model group,Yiqi Jianpi group, Yiqi Jianpi cancer group. There were10rats in each group.The blank control group were treated with normal saline; model group were givensaline, Yiqi Jianpi group were given Yiqi Jianpimedicine; Yiqi Jianpi anticancergroup were given Yiqi Jianpi anticancer medicine. The blank group and model group weretreated with normal saline for14days. The drug groups were given correspondingmedicine for14days.
5. Indicators: The first part of the experiment was the experimental study YiqiJianpi anticancer effects on gastric cancer in mice by absorption digestion,the indexs: nude mice weight, food intake and water intake, gastric residualrate, intestinal propulsion rate, determination of the content of somatostatinin small intestine and in plasma by radioimmunoassay. The second study was theeffects of Yiqi Jianpi anticancer on the PKC of mice spleen, the indexes:expression of PKC protein was detected by Western blot method.The third part of the experiment was observation on gastric cancer tumor growth in mice andtumor EGF, VEGF expression, the index: tumor weight, inhibition rate of tumor,and tumor cell apoptosis was determined by TUNEL method, the expression of thetumor EGF, VEGF were determined by Western-blot method.
Results：
1．Amounts of weight gain: blank group was5.99±0.24g, significantly more thanthe other three groups (P <0.05), model group was2.50±0.27g, and Yiqi Jianpigroup was4.21±0.35g, Yiqi Jianpi anticancer group was4.62±0.40g, the otherthree groups were better than the model group (P <0.05). No statisticalsignificance of Yiqi Jianpi group and Yiqi Jianpi anticancer group was observed,but the latter was better than the former trend. In the aspect of food intakeand water intake, showed the same results with the weight change, blank groupwas the best, followed by Yiqi Jianpi anticancer group, Yiqi Jianpi group andmodel group, the other three groups were better than model group.
2．gastric residual rate and intestinal propulsive rate: in the blank group,the gastric residual rate was31.2±11.4%and small intestinal propulsion ratewas65.4±9.6%, was the best in all groups, had the minimum gastric residualrate and the maximum small intestinal propulsion rate, there were significantdifference (P <0.05) compared with the other three groups, the difference ofYiqi Jianpi anticancer group and the blank group was minimum. In model group,the gastric residual rate was48.3±12.6%and small intestinal propulsion ratewas44.8±11.3%, was the worst in all groups, there were significant difference(P <0.05) compared with the other three groups. Yiqi Jianpi group, gastricresidual rate was39.7±11.2%, small intestinal propulsion rate was56.3±10.4%,Yiqi Jianpi anticancer group, gastric residual rate was35.5±10.7%, smallintestinal propulsion rate was60.1±10.2%, there was no difference between thetwo groups, but the Yiqi Jianpi anticancer group had a better trend to Yiqi Jianpigroup.
3. Somatostatin. the amounts of somatostatin were lowest in the blank group,the small intestine and the plasma levels were143±32ng/g and84±32ng/L. the amounts of somatostatin were the highest In the model group, were182±51ng/gand125±39ng/L; In Yiqi Jianpi group were177±46ng/g and110±42ng/L. In YiqiJianpi anticancer group were160±42ng/g and102±38ng/L. There were obviousdifferences between groups and the blank group (P <0.05). compared with themodel there was significant difference between Yiqi Jianpi group and the modelgroup (P <0.05), there was significant difference between Yiqi Jianpi anticancergroup and the model group also(P <0.05). Compared with the Yiqi Jianpi group,the Yiqi Jianpi anticancer group showed a good trend, but without statisticalsignificance.
4. Spleen coefficient: the spleen coefficient in blank group was1.17±0.12%,model group was0.71±0.24%, Yiqi Jianpi group was0.94±0.18%, Yiqi Jianpianticancer group was1.06±0.27%. Compared with the blank group, model groupand Yiqi Jianpi group were less than the blank group, there were statisticallysignificant (P <0.05); the Yiqi Jianpi anticancer group were little less thanthe blank group, but there was no significant difference between the two groups.Compared with the model group, spleen coefficient of the other three groups weresignificantly higher than model group, there were statistical significance (P<0.05).
5. The expression of PKC in the spleen: blank group was0.557±0.028, other groupswere Yiqi Jianpi anticancer group0.509±0.010, Yiqi Jianpi group0.442±0.017,model group0.419±0.021. Compared with the blank group, in the model group,the expression of PKC decreased most significantly (P<0.01), In Jianpi Yiqi groupand Yiqi Jianpi anticancer group, the expression of PKC also decreased (P<0.01,P<0.05). Compared with the model group, the expression of PKC were higher inJianpi Yiqi group and Yiqi Jianpi anticancer group,there were statisticalsignificance (P<0.01), the expression of PKC of Yiqi Jianpi anticancer groupwas highest in the three groups, but still lower than the blank group.
6.tumor weight and inhibition rate of tumor: the tumor weight of model group,Yiqi Jianpi group and Yiqi Jianpi anticancer group were3.82±0.73g,2.76±0.25gand2.44±0.37g, the tumor growth of the two groups were less than that in model group, there were statistical significance (P <0.05); the tumor weight of YiqiJianpi anticancer group was less than Yiqi Jianpi group, there was statisticallysignificant (P <0.05). The tumor inhibition rate of Yiqi Jianpi group amd YiqiJianpi anticancer group were28%,36%, there was obvious statisticalsignificance.
7. The number of apoptotic cells: the number of apoptotic cells of model group,Yiqi Jianpi group and Yiqi Jianpi anticancer group were0.80±0.79,7.30±1.57and18±2.45, Compared with the model group, the Yiqi Jianpi group and the YiqiJianpi anticancer group were higher, there were statistically significant (P<0.01). Compared with the Yiqi Jianpi group, the number of apoptotic cells ofthe Yiqi Jianpi anticancer group, was significantly more than the former, therewere statistically significant difference (P <0.01).
8. The expression of EGF, VEGF: model group, the expression of EGF, VEGF of modelwere the highest, the expression of Yiqi Jianpi groups were lower than the modelgroup, but there were no statistically significant; the expression of EGF, VEGFof Yiqi Jianpi anticancer group were significantly lower than that of the formertwo, there were statistically significant (P <0.05).
Conclusion：
1. Gastric cancer can affect the metabolic function of the spleen, the Yiqi JianpiChinese medicine can improve the spleen function, can strengthen gastricemptying and small intestinal propulsion, when the Yiqi Jianpi Chinese medicinewere used with the anticancer Chinese medicine together, the improve effect canbe more obvious.
2. Gastric cancer can inhibit the growth of spleen, inhibit the expression of spleenPKC, application of Yiqi Jianpi anticancer treatment, this inhibitory effectwas weakened.
3. Yiqi Jianpi anticancer treatment compared with the single Yiqi Jianpitreatment, the inhibitory effect on the tumor is more obvious, not only hadanticancer effects, but also can inhibit the expression of the EGF and VEGF,these were important genes related to tumor growth.
4. Gastric cancer can affect the function of the spleen, the application of YiqiJianpi anticancer treatment can achieve the dual goal of strengthening the spleenfunction and anticancer. Therefore, in clinical treatment, in the applicationof Yiqi Jianpi medicine, at the same time, the anticancer medicine should becombined, this combination principle embodies the combination of disease andsyndrome differentiation and treatment of TCM treatment philosophy, worthy offurther promotion.
引文
[1]于慧,殷东风.256例原发性胃癌中医证候及演变规律[J].中华中医药学刊，2012，30(7)：1654-1656.
[2]尹璐,殷东风.香砂六君子汤加减对胃癌术后患者中气重建影响的临床研究[J].中国现代医生，2009,47(7)：93-94.
[3]杨金祖.邱佳信关于胃癌学术思想的探讨[J].辽宁中医杂志,2001,28(2):80-81.
[4]邱佳信.健脾法为主治疗晚期胃癌的探讨[J].中医杂志,1992,33(8):23-25.
[5]石怀芝.孙桂芝辨证治疗中晚期胃癌的经验[J].北京中医杂志,2003,22(2):13-14.
[6]李和根.刘嘉湘治疗胃癌经验述要[J].辽宁中医杂志,2005,32(7):642.
[7]卜平,周荣卿,陈齐鸣.扶正化瘀方对胃癌转移及血液流变学的影响[J].中国中西医结合脾胃杂志,2000,8(4):193-195.
[8]王瑞平,潘宇,叶志超.健脾化瘀合剂配合化疗治疗晚期胃癌24例临床观察[J].江苏中医药,2004,25(11):22-23.
[9]朱国先.癌瘀相关初探[J].浙江中医杂志.2000,35(12):533-534.
[10]郑国静,魏品康.消痰散结法治疗胃癌的研究[J].中医药学报.2004,32(5):14-15.
[11]钱彦芳.肿瘤从痰论治探讨[J].中国中医基础医学杂志.1999,5(2):42-44.
[12]赵智强,李嘉.略论周仲瑛教授的癌毒学说及其临床运用[J].新中医,1998,30(10):6-8.
[13]陈继婷,翟信长,易玉斌.陈慈煦教授用通降解毒法治疗食道癌、胃癌临床经验浅析[J].贵阳中医学院学报,1995,17(3):17-18.
[14]申春悌.徐迪华运用豆芪汤治疗晚期胃癌的经验[J].江苏中医,1994,15(7):6-7.
[15]周兰.尹莲芳治疗胃癌的经验[J].辽宁中医杂志,1999,26(8):342-343.
[16]朱曾柏.因毒致癌及解毒治癌探析[J].辽宁中医杂志,1994,21(3):105-106.
[17]钱心兰.攻补兼施治疗胃癌113例[J].上海中医药杂志,1996,(2):7-9.
[18]王晓.辨证治疗晚期胃癌40例[J].江西中医药,1999,30(4):28-29.
[19]陈郭君.中医辨证分型治疗胃癌[J].湖北中医杂志,2000,22(3):19-19.
[20]董秀丽,于水莲.中晚期胃癌的中西医结合治疗的研究[J].医学综述，2008，14(9)：1336-1338.
[21]许玲，孙大志.胃癌中医证型分类的文献研究[J].世界华人消化杂志，2004，12(6)：1457-1459.
[22]杨继泉.中药治疗中晚期胃癌102例疗效分析[J].浙江中西医结合杂志,2000,(6):334.
[23]刘边林.中药治疗胃癌33例[J].陕西中医,1990,11(11):48.
[24]翟范.中药扶正抗癌方治疗中晚期消化道肿瘤160例观察[J].中国中西医结合消化杂志,1997,5(2):67.
[25]龚琼模，吴坷，甘淳等.辨证论治加化疗治疗Ⅱ、Ⅲ期胃癌术后患者39例的远期疗效分析[J].中国中西医结合脾胃杂志，1994，2(2)：54-56.
[26]吴曙光，吴晓丽.辨治胃癌化疗后血细胞减少116例[J].安徽中医学院学报，1996，15(6)：14-15.
[27]陈凯，王庆才，殷红等.化疗结合中医辩证治疗晚期胃癌的临床观察[J].中国临床保健杂志，2007，10(3)，275-277.
[28]黄兆明，程剑华，张所乐.Ⅱ、Ⅲ期胃癌手术后辨证论治加化疗远期疗效分析[J].江西中医药，1998，29(1)：25-26.
[29]刘毅，周洁.中西医结合治疗晚期胃癌30例[J].山东中医杂志，2002，21(3)：164-165.
[30]苏继忠，苏东平.贞芪扶正冲剂在UFTM联合治疗晚期胃癌中减毒作用的初步临床观察[J].中国肿瘤临床，1993，20(12)：929-931.
[31]孙兆和，李卫福. Ⅲ期胃癌术后中西医结合治疗之研究[J].实用中西医结合杂志，1998，11(8)：75.
[32]王锡恩，江浩.自拟健脾散结方联合化疗治疗晚期胃癌[J].浙江中西医结合杂志，2008，18(8)：500-501.
[33]刘庆林，曾姣飞.扶正抗癌合剂联合卡培他滨治疗31例晚期胃癌临床观察[J].中医药导报，2007，13(10)：27-28.
[34]李春香.健脾益胃养心汤对晚期胃癌化疗患者心理健康及生活质量的影响[J].中外医疗，2009(1)：90-91.
[35]朱龙洋，田莉.胃癌宁汤对38例晚期胃癌患者化疗后生活质量的影响[J].右江医学，2008，56(3)：525-527.
[36]石桓文，张保信.健胃隐消汤在胃癌术后应用的临床研究[J].滨州医学院学报，2008，31(5)：395-396.
[37]吴英举.加味香砂六君子汤治疗中晚期胃癌32例[J].河南中医，2008，28(9)：81-82.
[38]王佩.化疗、放疗加鸦胆子油乳注射液治疗晚期胃癌疗效观察[J].实用肿瘤杂志，2004，19(1)：78-79.
[39]周小宁，陈苏蓉.苦参素注射液联合XELOX方案治疗晚期胃癌临床观察[J].山西中医，2008，24(9)：18-19.
[40]韩鸿彬,陈嘉勇.华蟾素诱导人胃癌细胞株BGC-823凋亡实验研究[J].中国肿瘤,2008,17(3):233-235.
[41]叶淑芳，叶斌.参芪扶正注射液治疗老年中晚期胃癌[J].温州医学院学报，2009，39(2)：172-173.
[42]徐飚,王建明.胃癌流行病学研究[J].中华肿瘤防治杂志.2006,13(1):1-7.
[43]徐晶莹，李益民，李玉兰等.MNNG诱导大鼠胃癌模型的建立［J］.哈尔滨医科大学学报，2003，37（2）：104-106.
[44]吕岩红，李玉兰，董国刚，吴燕，李晓冬，宋燕妮.多因素诱导构建大鼠胃癌模型［J］.哈尔滨医科大学学报,2005,39（3）：226-228.
[45]耿敬姝，薛英威，刘秀华等.人消化道裸鼠移植瘤株及体外细胞系的建立［J］.实用肿瘤学杂志,2000,14（3）：162-164.
[46]刘平，赵志泉，张小勇等.人胃癌细胞悬液裸小鼠原位移植模型建立及其部分生物学特性［J］.南京医科大学学报,2000,20（6）：415-416.
[47]陶凯雄，田源，陈道达.鼠种植性胃肿瘤模型的制作方法及抗癌药物的治疗作用［J］.同济医科大学学报,2000,29(3):229-231.
[48]邓华，孙宁，唐慰萍等.人胃癌移植瘤演进过程中肥大细胞的研究［J］.广州医学院学报,2000,28(4):28-31.
[49]李茂全,沈建华,胥彬等.消癌平对SGC-7901胃癌细胞的作用及机制的实验研究[J].介入放射学杂志,2001,10(4):228-231
[50]孙波.鸦胆子油乳抗人胃癌增殖作用的初步研究[J].上海医学,2001，24(8):481-483.
[51]王海燕，郭良淼，陈勇等．槲皮素对胃癌MGC-803细胞生长及凋亡作用的研究[J]．中国药房,2006，17(19)：1455-1456．
[52]朱艳琴．苦参素诱导人胃癌细胞系MGC-803凋亡的研究[J]．中国社区医师,2006，8(20)：21-22．
[53]孙抒，金哲，李基俊．蛴螬提取物体外对人MGC-803胃癌细胞株的抗增殖及诱导凋亡作用的形态学观察[J]．四川中医，2005,23(2)：12-15．
[54]黄恺飞，陆云华，何睿等．藤黄酸对胃癌BGC-803细胞凋亡的作用及对survivin基因表达的影响[J].中国药科大学学报,2008，39(5)：474-478．
[55]胡淑婷，奥海航，王英华等．小叶黑柴胡诱导人胃腺癌MGC-803细胞凋亡的实验研究[J]．宁夏医学院学报，2007，29(1)：13-15．
[56]梁枫，王明艳，等.斑鳌酸钠诱导人胃癌BGC823细胞凋亡的实验研究.南京中医药大学学报，2006,22(3):171-172.
[57]涂晓坤，赵刚等.姜黄素对SGC7901和HepG2两种细胞株生长和凋亡的影响[J].江西中医学院学报，2006,7(3):25-26.
[58]郑杰，刘艳平等.红车轴草提取物对胃癌细胞株BGC-823细胞凋亡的影响[J].生命科学研究,2006,10(2):178-182.
[59]王馄，董惠芳等.夏枯草对SGC-79U1细胞的影响[J].上海医学检验杂志,2000,15(5):305-307.
[60]赵君宁，何一然等.青蒿素对人胃癌细胞增殖及凋亡的影响[J].中国癌症杂志，2005,15(4):347-350.
[61]宗永立，刘艳平.白屈菜红碱对人胃癌BGC-823细胞的增殖抑制和凋亡诱导作用[J].中草药，2006,37(7):1054-1056.
[62]孟书聪，董晓敏等.脂蟾毒配基对人胃癌BGC-823细胞系细胞生长的干预效应[J].中国临床康复，2006,10(43):138-142.
[63]陈小义，徐瑞成等.蟾蛤灵诱导人胃癌细胞凋亡的实验研究[J].基础医学与临床，2000,20(5):50-53.
[64]李玉梅，符乃阳等.甘草提取物体外选择性诱导几种人肿瘤细胞凋亡[J].癌症，2001,20(8):806-811.
[65]吕晓英，李由等.红毛五加多糖诱导体外人胃癌细胞凋亡的研究[J].实用癌症杂志，2001,16(1):6-8.
[66]吕晓英，曾令福等.红毛五加多糖一I诱导体外人胃癌细胞凋亡的研究[J].华西医科大学学报，2002,33(2):165-168.
[67]董晓荣，伍钢等.月一参酮IIA对MKN-45细胞生长的影响[J].肿瘤防治杂志，2005,12(19):1465-1468.
[68]黄敬群，王四旺等.桂皮醛对裸鼠人胃癌细胞移植瘤生长及凋亡的影响[J].解放军药学学报，2006,22(05):343-346.
[69]叶红军，房家智.刺五加叶皂试诱导胃癌细胞凋亡的探讨[J].国老年学杂志，1999,19(11):338-339.
[70]唐晓颇，孙桂芝，吴洁等．健脾补肾方对胃癌细胞系MGC-803线粒体膜电位和细胞内活性氧的影响[J].中国实验方剂学杂志，2005，11(6)：61-64．
[71]王晓华，单兆伟．芪竹方对人胃腺癌MGC-803细胞Caspase-3及端粒酶增殖与凋亡的影响[J]．中国中西医结合消化杂志，2006，14(2)：90-92．
[72]许岸高，刘集鸿等.黄参方剂治疗胃癌中的细胞凋亡及一氧化氮改变[J].中国实用内科杂志，2001,21(4):225-226.
[73]赵爱光，杨金坤等.四君子汤诱导裸小鼠移植性人胃癌细胞凋亡的初步研究[J].癌症，2001，20(2):164-167.
[74]苏勉诚，吕晓英等.癌宁诱导体外人胃腺癌细胞SGC-7901凋亡及细胞周期分析[J].中药材，2001,24(12):876-879.
[75]陈泽雄，张诗军等.中药复方对人肿瘤细胞凋亡的研究进展[J].中药材，2000,23(8):477-479.
[76]杨勤建，雷良蔚.香龙散诱导人胃癌细胞凋亡的机理探讨[J].中医杂志，2000,41(7):428-430.
[77]何玉军.中药复方软坚消肿液抑瘤实验[J].医学理论与实践，1999,12(10):568.
[78]余志红，魏品康等.金龙蛇颗粒对裸鼠原位移植人胃癌MKN-45细胞凋亡的影响[J].中西医结合学报，2006,4(03):275-280.
[79]刘继林，李红坤等.中药复方癌宁对人胃腺癌细胞凋亡基因表达的影响[J].中药材，2002,25(8):563-566.
[80]梁健，邓鑫等.胃宁方对人胃癌SGC-7901细胞增殖凋亡的影响[J].上海中医药杂志，2006,40(09):65-67.
[81]席时燕，刘喜平等.半夏泻心方及其配伍药组含药血清对人胃癌BGC-823细胞增殖及Bcl-2表达的影响[J].中国中医药信息杂志，2006,13(04):20-22.
[82]汪永锋，刘喜平等.半夏泻心方配伍药组含药血清对人胃癌细胞凋亡及凋亡相关基因的影响[J].中国中医药信息杂志，2006,13(05):27-29.
[83]冯春霞，李庆明.胃康宁含药血清对胃癌MGC-803细胞增殖的抑制作用及机理研究[J].中药材，2006,29(05)：456-458.
[84]郎玮，谢泳泳等.扶正消瘤方药液诱导胃癌细胞凋亡的实验研究[J].中国中医药科技，2006,13(05)：296-299.
[85]唐犁，李志宏等.双灵固本散对人胃癌细胞凋亡相关基因表达调节的研究[J].浙江中医杂志，2006,41(09)：526-528.
[86]田涛，杨秋滋.乐胃煎对大鼠胃粘膜上皮异型增生细胞凋亡及调控基因的影响[J].中国中西医结合脾胃杂志，2000,8(02):67-69.
[87]田涛，杨勤建等.香龙散诱导人胃癌细胞凋亡的机理探讨[J].中医杂志，2000,41(7):428-430.
[88]刘永衡，孙桂芝，张培彤.中药诱导人胃癌MGC-803细胞凋亡研究近况[J].天津中医药,2009,26(6):522-533.
[89]石彦，余佩武等.复方苦参注射液对胃癌术后化疗患者免疫功能的影响[J].药学服务与研究，2006，6(3):183-185.
[90]范针，张尤历等.榄香烯乳对胃癌细胞人端粒酶反转录酶及其启动子的影响[J].江苏大学学报(医学版),2006,16(5):413-415.
[91]梅武轩,曾常春,余娜.益气化瘀中药对大鼠胃癌前病变蛋白激酶C及细胞周期素E蛋白表达的影响[J].中国中医药信息杂志，2008,15(3)：26-27.
[92]闵存云,李庆明,吴伟康等.中药复方胃康宁对人胃癌细胞及其受体表达的作用[J].世界华人消化道杂志,2004,12(3):533-536.
[93]闵存云,刘和强,李庆明.健脾导滞中药对胃癌细胞及其受体表达的作用[J].中华实用中西医杂志,2005,18(9):1351-1352.
[94]张旭晨,赵凤志,代欣等.消痞灵冲剂对实验性胃癌前病变大鼠胃粘膜胃螺旋样菌感染的防治作用[J].北京中医药大学学报,1995,18(4):59.
[95]李静.p16、bcl-2基因蛋白在胃癌和癌前病变的表达及意义[J].锦州医学院学报,2005,26(2):1.
[96]裘莹.bcl-2蛋白与胃癌相关性的研究[J].同济大学学报学版,2001,22(1):25.
[97]王小娟,尹莉.bcl-2基因及Survivin基因与胃癌的研究进展[J].宁夏医学杂志,2006,28(1):78.
[98]王宗柱,葛震,王永杰等.加味四逆泻心汤对实验性大鼠胃癌前病变p16及bcl-2基因表达的影响[J].四川中医,2009,27(7):34-36.
[99]肖艳,魏品康,许玲等.消痰散结方对裸鼠MKN-45人胃癌组织中MMP2表达的影响[J].成都中医药大学学报，2002，25（4）：32-33.
[100]魏品康，许玲，秦志丰等.胃癌从痰论治的机理与临床研究[J].中国中医基础医学杂志，2002，8（2）：18-20.
[101]赵爱光，杨金坤，尤圣富等.中药胃肠交诱导裸鼠胃癌移植瘤细胞凋亡的途径及基因调控的研究[J].中西医结合学报，2007,5(3):287.
[102]彭成,雷载权.四君子汤抗脾虚动物胃肠细胞损伤的研究[J].中药药理与临床,1995,11(6):7.
[103]王洪海,谢鸣.复合因素致脾虚证模型大鼠血中胃肠激素含量的变化[J].中国实验方剂学杂志,2006,12(10):30-35.
[104]严茂祥,陈芝芸,项柏康.脾虚证大鼠血及结肠组织胃肠激素的变化[J].中国医药学报,2003,18(2):71-72.
[105]宋述财,邓中炎,陈群等.脾虚湿困及其它脾胃虚实证的胃肠道症状与胃电频谱改变[J].广东医学,1997,18(11):757-759.
[106]李燕舞,王汝俊,王建华.大黄脾虚模型大鼠胃壁细胞的超微结构观察[J].中国中西医结合消化杂志,2005(3):155-157.
[107]李岩,陈苏宁,田代真一.葡聚糖蓝2000标记五积散对鼠胃排空及小肠推进功能的影响.中国医科大学学报,1996(25):160-161.
[108]任平,黄熙,张莉等.四君子汤对实验性脾虚大鼠胃排空率的影响[J].中国中西医结合杂志,2000,20(8):596-598.
[109]朱颖,殷东风.运用调理脾胃中药提高晚期肿瘤患者生存质量的临床分析[J].中国中医基础医学杂志，2006,12(9):685-687.
[110]刘健,孙弼纲.脾虚泄泻患者红细胞免疫功能的临床研究[J].中国中西医结合杂志,1994,14(9):531.
[111]章梅,夏天,张仲海.脾虚小鼠红细胞免疫和腹腔巨噬细胞吞噬功能改变的实验研究[J].北京中医药大学学报,1999,22(3)：27-28.
[112]章梅,夏天,南耘等.脾虚患者血浆纤维连接蛋白和巨噬细胞功能的变化[J].浙江中医学院学报,1999,23(5):36.
[113]关崇芬,沈华.蛋白酪氨激酶与中医脾虚证研究[J].中国中医药信息杂志,1996,3(11):14.
[114]刘春明,李德新.脾阳虚大鼠肝脾蛋白激酶C活性的实验研究[J].辽宁中医杂志,2000,27(1)：44-45.
[115]易杰,李德新等.脾阳虚大鼠脾、肝和肾组织蛋白激酶C活性变化的研究[J].中医药学刊,2002,20(1)：39-40.
[116]魏睦新,贝淑英.脾阴虚证体液免疫功能初探[J].南京医学院学报,1988,8(1):53-54.
[117]王彩霞.滋补脾胃法治疗老年性痴呆作用机理的实验研究[J].辽宁中医杂志,2000,27(10)：477.
[118]武继彪，张玲.酸枣茶的药理研究[J].时珍国药研究,1996,7(2)：91.
[119]张暋,梁东辉,李小敏等.脑血管病辨证分型与血清脂蛋白及胆固醇水平的研究[J].实用中西医结合杂志,1995,8(7):392.
[120]王秀琴.大鼠实验性脾虚证空肠粘膜吸收细胞ATP酶的细胞化学研究[J].中国组织化学与细胞化学杂志,1997,(4):60-63.
[121]王肃,陈小野,邹世洁等.利血平脾虚证模型大脑皮层基因表达谱变化的初步研究[J].中医药学刊,2003,(09):1512-1515.
[122]钱会南,许红,沈丽波.健脾与补肾对脾虚模型大鼠学习记忆及脑内P物质、血管活性肠肽的影响[J].中国中医药信息杂志,2007,(01):37-38.
[123]杨传标,薛军,殷平善等.大肠癌脾虚证bcl-2基因表达与健脾康复汤的调节作用[J].第一军医大学学报,2005,(10):1268-1269.
[124]易杰,李德新.脾虚证动物模型研究思路和方法探析[J].上海中医药杂志,2001,35(05):40-42.
[125]易杰,李德新.脾气虚大鼠脾肝组织蛋白激酶C活性变化的实验研究[J].辽宁中医杂志,2002,29(6):374-375.
[126]易杰,李德新.脾气虚与脾阳虚大鼠肝脾组织蛋白激酶C活性变化的研究[J].中医药学刊,2002,20(5):639-644.
[127]冯利.简明中西医结合肿瘤病学[M].北京:科技文献出版社,2008.
[128]席孝贤,贺新怀.试论中药对肿瘤细胞的多靶点效应[J].陕西中医,2002,23(7):641-644.
[129]韩凤娟.中医药防治肿瘤作用机制的现代研究思路与探索[J].江苏中医药,2003,24(5):9-12.
[130]何赛萍.中药抗肿瘤研究思路[J].浙江中医学院学报,2001,25(4):61-62.
[131]周劬志.中药抗肿瘤血管生成研究述略[J].中国处方药,2004,29(8):30.
[132] Bergsland EK. Vascular endothelial growth factor as a therapeutic targetin cancer[J]. American Journal of Health System Pharmacy,2004,61(21):4-11.
[133]钱士辉.陈皮提取物体内抗肿瘤作用及其对癌细胞增殖周期的影响[J].中国中药杂志，2003,28(12):1167-1169.
[134]张会军,阎蕴力,张朱欣等.川芎嗪对人小细胞肺癌H446细胞的增殖抑制作用[J].肿瘤防治研究,2003,30(6):452.
[135]梁文杰,单保恩.中药拮抗P-糖蛋白介导的肿瘤多药耐药机制的研究进展[J].中草药,2004,34(4):466-469.
[136]秦善文,郑玉玲.抗肿瘤中药实验研究进展[J].河南中医，2005,25(2):76-78.
[137]何赛萍.中药抗肿瘤研究思路[J].浙江中医学院学报,2001,25(4):61-62.
[138]朱曰林,张一楚等.C-erbB2和EGFR在胃癌中表达的研究[J].中国肿瘤临床,1996,23(12):855-859.
[139]Hunter T.The epidermal growth factor receptor gene and its product[J].Nature,1984,311(5985):414-416.
[140]郝远瑞,丁贯一等.大肠癌EGF受体表达对细胞增殖的影响[J].华人消化杂志,1998,6(4):313-314.
[141]谭祥华,黄秀深等.青莪汤对Lewis肺癌小鼠MMP9、Ang-Ⅱ、EGF、微血管密度的影响[J].长春中医药大学学报,2010,1(8):14-15.
[142]唐广义,殷东风.肠积宁方促进大肠癌细胞株HT-29凋亡及干预相关基因bcl-2及bax表达的实验研究[J].现代肿瘤医学,2007,15(4):491-493.
[2]尹璐,殷东风.香砂六君子汤加减对胃癌术后患者中气重建影响的临床研究[J].中国现代医生，2009,47(7)：93-94.
[3]杨金祖.邱佳信关于胃癌学术思想的探讨[J].辽宁中医杂志,2001,28(2):80-81.
[4]邱佳信.健脾法为主治疗晚期胃癌的探讨[J].中医杂志,1992,33(8):23-25.
[5]石怀芝.孙桂芝辨证治疗中晚期胃癌的经验[J].北京中医杂志,2003,22(2):13-14.
[6]李和根.刘嘉湘治疗胃癌经验述要[J].辽宁中医杂志,2005,32(7):642.
[7]卜平,周荣卿,陈齐鸣.扶正化瘀方对胃癌转移及血液流变学的影响[J].中国中西医结合脾胃杂志,2000,8(4):193-195.
[8]王瑞平,潘宇,叶志超.健脾化瘀合剂配合化疗治疗晚期胃癌24例临床观察[J].江苏中医药,2004,25(11):22-23.
[9]朱国先.癌瘀相关初探[J].浙江中医杂志.2000,35(12):533-534.
[10]郑国静,魏品康.消痰散结法治疗胃癌的研究[J].中医药学报.2004,32(5):14-15.
[11]钱彦芳.肿瘤从痰论治探讨[J].中国中医基础医学杂志.1999,5(2):42-44.
[12]赵智强,李嘉.略论周仲瑛教授的癌毒学说及其临床运用[J].新中医,1998,30(10):6-8.
[13]陈继婷,翟信长,易玉斌.陈慈煦教授用通降解毒法治疗食道癌、胃癌临床经验浅析[J].贵阳中医学院学报,1995,17(3):17-18.
[14]申春悌.徐迪华运用豆芪汤治疗晚期胃癌的经验[J].江苏中医,1994,15(7):6-7.
[15]周兰.尹莲芳治疗胃癌的经验[J].辽宁中医杂志,1999,26(8):342-343.
[16]朱曾柏.因毒致癌及解毒治癌探析[J].辽宁中医杂志,1994,21(3):105-106.
[17]钱心兰.攻补兼施治疗胃癌113例[J].上海中医药杂志,1996,(2):7-9.
[18]王晓.辨证治疗晚期胃癌40例[J].江西中医药,1999,30(4):28-29.
[19]陈郭君.中医辨证分型治疗胃癌[J].湖北中医杂志,2000,22(3):19-19.
[20]董秀丽,于水莲.中晚期胃癌的中西医结合治疗的研究[J].医学综述，2008，14(9)：1336-1338.
[21]许玲，孙大志.胃癌中医证型分类的文献研究[J].世界华人消化杂志，2004，12(6)：1457-1459.
[22]杨继泉.中药治疗中晚期胃癌102例疗效分析[J].浙江中西医结合杂志,2000,(6):334.
[23]刘边林.中药治疗胃癌33例[J].陕西中医,1990,11(11):48.
[24]翟范.中药扶正抗癌方治疗中晚期消化道肿瘤160例观察[J].中国中西医结合消化杂志,1997,5(2):67.
[25]龚琼模，吴坷，甘淳等.辨证论治加化疗治疗Ⅱ、Ⅲ期胃癌术后患者39例的远期疗效分析[J].中国中西医结合脾胃杂志，1994，2(2)：54-56.
[26]吴曙光，吴晓丽.辨治胃癌化疗后血细胞减少116例[J].安徽中医学院学报，1996，15(6)：14-15.
[27]陈凯，王庆才，殷红等.化疗结合中医辩证治疗晚期胃癌的临床观察[J].中国临床保健杂志，2007，10(3)，275-277.
[28]黄兆明，程剑华，张所乐.Ⅱ、Ⅲ期胃癌手术后辨证论治加化疗远期疗效分析[J].江西中医药，1998，29(1)：25-26.
[29]刘毅，周洁.中西医结合治疗晚期胃癌30例[J].山东中医杂志，2002，21(3)：164-165.
[30]苏继忠，苏东平.贞芪扶正冲剂在UFTM联合治疗晚期胃癌中减毒作用的初步临床观察[J].中国肿瘤临床，1993，20(12)：929-931.
[31]孙兆和，李卫福. Ⅲ期胃癌术后中西医结合治疗之研究[J].实用中西医结合杂志，1998，11(8)：75.
[32]王锡恩，江浩.自拟健脾散结方联合化疗治疗晚期胃癌[J].浙江中西医结合杂志，2008，18(8)：500-501.
[33]刘庆林，曾姣飞.扶正抗癌合剂联合卡培他滨治疗31例晚期胃癌临床观察[J].中医药导报，2007，13(10)：27-28.
[34]李春香.健脾益胃养心汤对晚期胃癌化疗患者心理健康及生活质量的影响[J].中外医疗，2009(1)：90-91.
[35]朱龙洋，田莉.胃癌宁汤对38例晚期胃癌患者化疗后生活质量的影响[J].右江医学，2008，56(3)：525-527.
[36]石桓文，张保信.健胃隐消汤在胃癌术后应用的临床研究[J].滨州医学院学报，2008，31(5)：395-396.
[37]吴英举.加味香砂六君子汤治疗中晚期胃癌32例[J].河南中医，2008，28(9)：81-82.
[38]王佩.化疗、放疗加鸦胆子油乳注射液治疗晚期胃癌疗效观察[J].实用肿瘤杂志，2004，19(1)：78-79.
[39]周小宁，陈苏蓉.苦参素注射液联合XELOX方案治疗晚期胃癌临床观察[J].山西中医，2008，24(9)：18-19.
[40]韩鸿彬,陈嘉勇.华蟾素诱导人胃癌细胞株BGC-823凋亡实验研究[J].中国肿瘤,2008,17(3):233-235.
[41]叶淑芳，叶斌.参芪扶正注射液治疗老年中晚期胃癌[J].温州医学院学报，2009，39(2)：172-173.
[42]徐飚,王建明.胃癌流行病学研究[J].中华肿瘤防治杂志.2006,13(1):1-7.
[43]徐晶莹，李益民，李玉兰等.MNNG诱导大鼠胃癌模型的建立［J］.哈尔滨医科大学学报，2003，37（2）：104-106.
[44]吕岩红，李玉兰，董国刚，吴燕，李晓冬，宋燕妮.多因素诱导构建大鼠胃癌模型［J］.哈尔滨医科大学学报,2005,39（3）：226-228.
[45]耿敬姝，薛英威，刘秀华等.人消化道裸鼠移植瘤株及体外细胞系的建立［J］.实用肿瘤学杂志,2000,14（3）：162-164.
[46]刘平，赵志泉，张小勇等.人胃癌细胞悬液裸小鼠原位移植模型建立及其部分生物学特性［J］.南京医科大学学报,2000,20（6）：415-416.
[47]陶凯雄，田源，陈道达.鼠种植性胃肿瘤模型的制作方法及抗癌药物的治疗作用［J］.同济医科大学学报,2000,29(3):229-231.
[48]邓华，孙宁，唐慰萍等.人胃癌移植瘤演进过程中肥大细胞的研究［J］.广州医学院学报,2000,28(4):28-31.
[49]李茂全,沈建华,胥彬等.消癌平对SGC-7901胃癌细胞的作用及机制的实验研究[J].介入放射学杂志,2001,10(4):228-231
[50]孙波.鸦胆子油乳抗人胃癌增殖作用的初步研究[J].上海医学,2001，24(8):481-483.
[51]王海燕，郭良淼，陈勇等．槲皮素对胃癌MGC-803细胞生长及凋亡作用的研究[J]．中国药房,2006，17(19)：1455-1456．
[52]朱艳琴．苦参素诱导人胃癌细胞系MGC-803凋亡的研究[J]．中国社区医师,2006，8(20)：21-22．
[53]孙抒，金哲，李基俊．蛴螬提取物体外对人MGC-803胃癌细胞株的抗增殖及诱导凋亡作用的形态学观察[J]．四川中医，2005,23(2)：12-15．
[54]黄恺飞，陆云华，何睿等．藤黄酸对胃癌BGC-803细胞凋亡的作用及对survivin基因表达的影响[J].中国药科大学学报,2008，39(5)：474-478．
[55]胡淑婷，奥海航，王英华等．小叶黑柴胡诱导人胃腺癌MGC-803细胞凋亡的实验研究[J]．宁夏医学院学报，2007，29(1)：13-15．
[56]梁枫，王明艳，等.斑鳌酸钠诱导人胃癌BGC823细胞凋亡的实验研究.南京中医药大学学报，2006,22(3):171-172.
[57]涂晓坤，赵刚等.姜黄素对SGC7901和HepG2两种细胞株生长和凋亡的影响[J].江西中医学院学报，2006,7(3):25-26.
[58]郑杰，刘艳平等.红车轴草提取物对胃癌细胞株BGC-823细胞凋亡的影响[J].生命科学研究,2006,10(2):178-182.
[59]王馄，董惠芳等.夏枯草对SGC-79U1细胞的影响[J].上海医学检验杂志,2000,15(5):305-307.
[60]赵君宁，何一然等.青蒿素对人胃癌细胞增殖及凋亡的影响[J].中国癌症杂志，2005,15(4):347-350.
[61]宗永立，刘艳平.白屈菜红碱对人胃癌BGC-823细胞的增殖抑制和凋亡诱导作用[J].中草药，2006,37(7):1054-1056.
[62]孟书聪，董晓敏等.脂蟾毒配基对人胃癌BGC-823细胞系细胞生长的干预效应[J].中国临床康复，2006,10(43):138-142.
[63]陈小义，徐瑞成等.蟾蛤灵诱导人胃癌细胞凋亡的实验研究[J].基础医学与临床，2000,20(5):50-53.
[64]李玉梅，符乃阳等.甘草提取物体外选择性诱导几种人肿瘤细胞凋亡[J].癌症，2001,20(8):806-811.
[65]吕晓英，李由等.红毛五加多糖诱导体外人胃癌细胞凋亡的研究[J].实用癌症杂志，2001,16(1):6-8.
[66]吕晓英，曾令福等.红毛五加多糖一I诱导体外人胃癌细胞凋亡的研究[J].华西医科大学学报，2002,33(2):165-168.
[67]董晓荣，伍钢等.月一参酮IIA对MKN-45细胞生长的影响[J].肿瘤防治杂志，2005,12(19):1465-1468.
[68]黄敬群，王四旺等.桂皮醛对裸鼠人胃癌细胞移植瘤生长及凋亡的影响[J].解放军药学学报，2006,22(05):343-346.
[69]叶红军，房家智.刺五加叶皂试诱导胃癌细胞凋亡的探讨[J].国老年学杂志，1999,19(11):338-339.
[70]唐晓颇，孙桂芝，吴洁等．健脾补肾方对胃癌细胞系MGC-803线粒体膜电位和细胞内活性氧的影响[J].中国实验方剂学杂志，2005，11(6)：61-64．
[71]王晓华，单兆伟．芪竹方对人胃腺癌MGC-803细胞Caspase-3及端粒酶增殖与凋亡的影响[J]．中国中西医结合消化杂志，2006，14(2)：90-92．
[72]许岸高，刘集鸿等.黄参方剂治疗胃癌中的细胞凋亡及一氧化氮改变[J].中国实用内科杂志，2001,21(4):225-226.
[73]赵爱光，杨金坤等.四君子汤诱导裸小鼠移植性人胃癌细胞凋亡的初步研究[J].癌症，2001，20(2):164-167.
[74]苏勉诚，吕晓英等.癌宁诱导体外人胃腺癌细胞SGC-7901凋亡及细胞周期分析[J].中药材，2001,24(12):876-879.
[75]陈泽雄，张诗军等.中药复方对人肿瘤细胞凋亡的研究进展[J].中药材，2000,23(8):477-479.
[76]杨勤建，雷良蔚.香龙散诱导人胃癌细胞凋亡的机理探讨[J].中医杂志，2000,41(7):428-430.
[77]何玉军.中药复方软坚消肿液抑瘤实验[J].医学理论与实践，1999,12(10):568.
[78]余志红，魏品康等.金龙蛇颗粒对裸鼠原位移植人胃癌MKN-45细胞凋亡的影响[J].中西医结合学报，2006,4(03):275-280.
[79]刘继林，李红坤等.中药复方癌宁对人胃腺癌细胞凋亡基因表达的影响[J].中药材，2002,25(8):563-566.
[80]梁健，邓鑫等.胃宁方对人胃癌SGC-7901细胞增殖凋亡的影响[J].上海中医药杂志，2006,40(09):65-67.
[81]席时燕，刘喜平等.半夏泻心方及其配伍药组含药血清对人胃癌BGC-823细胞增殖及Bcl-2表达的影响[J].中国中医药信息杂志，2006,13(04):20-22.
[82]汪永锋，刘喜平等.半夏泻心方配伍药组含药血清对人胃癌细胞凋亡及凋亡相关基因的影响[J].中国中医药信息杂志，2006,13(05):27-29.
[83]冯春霞，李庆明.胃康宁含药血清对胃癌MGC-803细胞增殖的抑制作用及机理研究[J].中药材，2006,29(05)：456-458.
[84]郎玮，谢泳泳等.扶正消瘤方药液诱导胃癌细胞凋亡的实验研究[J].中国中医药科技，2006,13(05)：296-299.
[85]唐犁，李志宏等.双灵固本散对人胃癌细胞凋亡相关基因表达调节的研究[J].浙江中医杂志，2006,41(09)：526-528.
[86]田涛，杨秋滋.乐胃煎对大鼠胃粘膜上皮异型增生细胞凋亡及调控基因的影响[J].中国中西医结合脾胃杂志，2000,8(02):67-69.
[87]田涛，杨勤建等.香龙散诱导人胃癌细胞凋亡的机理探讨[J].中医杂志，2000,41(7):428-430.
[88]刘永衡，孙桂芝，张培彤.中药诱导人胃癌MGC-803细胞凋亡研究近况[J].天津中医药,2009,26(6):522-533.
[89]石彦，余佩武等.复方苦参注射液对胃癌术后化疗患者免疫功能的影响[J].药学服务与研究，2006，6(3):183-185.
[90]范针，张尤历等.榄香烯乳对胃癌细胞人端粒酶反转录酶及其启动子的影响[J].江苏大学学报(医学版),2006,16(5):413-415.
[91]梅武轩,曾常春,余娜.益气化瘀中药对大鼠胃癌前病变蛋白激酶C及细胞周期素E蛋白表达的影响[J].中国中医药信息杂志，2008,15(3)：26-27.
[92]闵存云,李庆明,吴伟康等.中药复方胃康宁对人胃癌细胞及其受体表达的作用[J].世界华人消化道杂志,2004,12(3):533-536.
[93]闵存云,刘和强,李庆明.健脾导滞中药对胃癌细胞及其受体表达的作用[J].中华实用中西医杂志,2005,18(9):1351-1352.
[94]张旭晨,赵凤志,代欣等.消痞灵冲剂对实验性胃癌前病变大鼠胃粘膜胃螺旋样菌感染的防治作用[J].北京中医药大学学报,1995,18(4):59.
[95]李静.p16、bcl-2基因蛋白在胃癌和癌前病变的表达及意义[J].锦州医学院学报,2005,26(2):1.
[96]裘莹.bcl-2蛋白与胃癌相关性的研究[J].同济大学学报学版,2001,22(1):25.
[97]王小娟,尹莉.bcl-2基因及Survivin基因与胃癌的研究进展[J].宁夏医学杂志,2006,28(1):78.
[98]王宗柱,葛震,王永杰等.加味四逆泻心汤对实验性大鼠胃癌前病变p16及bcl-2基因表达的影响[J].四川中医,2009,27(7):34-36.
[99]肖艳,魏品康,许玲等.消痰散结方对裸鼠MKN-45人胃癌组织中MMP2表达的影响[J].成都中医药大学学报，2002，25（4）：32-33.
[100]魏品康，许玲，秦志丰等.胃癌从痰论治的机理与临床研究[J].中国中医基础医学杂志，2002，8（2）：18-20.
[101]赵爱光，杨金坤，尤圣富等.中药胃肠交诱导裸鼠胃癌移植瘤细胞凋亡的途径及基因调控的研究[J].中西医结合学报，2007,5(3):287.
[102]彭成,雷载权.四君子汤抗脾虚动物胃肠细胞损伤的研究[J].中药药理与临床,1995,11(6):7.
[103]王洪海,谢鸣.复合因素致脾虚证模型大鼠血中胃肠激素含量的变化[J].中国实验方剂学杂志,2006,12(10):30-35.
[104]严茂祥,陈芝芸,项柏康.脾虚证大鼠血及结肠组织胃肠激素的变化[J].中国医药学报,2003,18(2):71-72.
[105]宋述财,邓中炎,陈群等.脾虚湿困及其它脾胃虚实证的胃肠道症状与胃电频谱改变[J].广东医学,1997,18(11):757-759.
[106]李燕舞,王汝俊,王建华.大黄脾虚模型大鼠胃壁细胞的超微结构观察[J].中国中西医结合消化杂志,2005(3):155-157.
[107]李岩,陈苏宁,田代真一.葡聚糖蓝2000标记五积散对鼠胃排空及小肠推进功能的影响.中国医科大学学报,1996(25):160-161.
[108]任平,黄熙,张莉等.四君子汤对实验性脾虚大鼠胃排空率的影响[J].中国中西医结合杂志,2000,20(8):596-598.
[109]朱颖,殷东风.运用调理脾胃中药提高晚期肿瘤患者生存质量的临床分析[J].中国中医基础医学杂志，2006,12(9):685-687.
[110]刘健,孙弼纲.脾虚泄泻患者红细胞免疫功能的临床研究[J].中国中西医结合杂志,1994,14(9):531.
[111]章梅,夏天,张仲海.脾虚小鼠红细胞免疫和腹腔巨噬细胞吞噬功能改变的实验研究[J].北京中医药大学学报,1999,22(3)：27-28.
[112]章梅,夏天,南耘等.脾虚患者血浆纤维连接蛋白和巨噬细胞功能的变化[J].浙江中医学院学报,1999,23(5):36.
[113]关崇芬,沈华.蛋白酪氨激酶与中医脾虚证研究[J].中国中医药信息杂志,1996,3(11):14.
[114]刘春明,李德新.脾阳虚大鼠肝脾蛋白激酶C活性的实验研究[J].辽宁中医杂志,2000,27(1)：44-45.
[115]易杰,李德新等.脾阳虚大鼠脾、肝和肾组织蛋白激酶C活性变化的研究[J].中医药学刊,2002,20(1)：39-40.
[116]魏睦新,贝淑英.脾阴虚证体液免疫功能初探[J].南京医学院学报,1988,8(1):53-54.
[117]王彩霞.滋补脾胃法治疗老年性痴呆作用机理的实验研究[J].辽宁中医杂志,2000,27(10)：477.
[118]武继彪，张玲.酸枣茶的药理研究[J].时珍国药研究,1996,7(2)：91.
[119]张暋,梁东辉,李小敏等.脑血管病辨证分型与血清脂蛋白及胆固醇水平的研究[J].实用中西医结合杂志,1995,8(7):392.
[120]王秀琴.大鼠实验性脾虚证空肠粘膜吸收细胞ATP酶的细胞化学研究[J].中国组织化学与细胞化学杂志,1997,(4):60-63.
[121]王肃,陈小野,邹世洁等.利血平脾虚证模型大脑皮层基因表达谱变化的初步研究[J].中医药学刊,2003,(09):1512-1515.
[122]钱会南,许红,沈丽波.健脾与补肾对脾虚模型大鼠学习记忆及脑内P物质、血管活性肠肽的影响[J].中国中医药信息杂志,2007,(01):37-38.
[123]杨传标,薛军,殷平善等.大肠癌脾虚证bcl-2基因表达与健脾康复汤的调节作用[J].第一军医大学学报,2005,(10):1268-1269.
[124]易杰,李德新.脾虚证动物模型研究思路和方法探析[J].上海中医药杂志,2001,35(05):40-42.
[125]易杰,李德新.脾气虚大鼠脾肝组织蛋白激酶C活性变化的实验研究[J].辽宁中医杂志,2002,29(6):374-375.
[126]易杰,李德新.脾气虚与脾阳虚大鼠肝脾组织蛋白激酶C活性变化的研究[J].中医药学刊,2002,20(5):639-644.
[127]冯利.简明中西医结合肿瘤病学[M].北京:科技文献出版社,2008.
[128]席孝贤,贺新怀.试论中药对肿瘤细胞的多靶点效应[J].陕西中医,2002,23(7):641-644.
[129]韩凤娟.中医药防治肿瘤作用机制的现代研究思路与探索[J].江苏中医药,2003,24(5):9-12.
[130]何赛萍.中药抗肿瘤研究思路[J].浙江中医学院学报,2001,25(4):61-62.
[131]周劬志.中药抗肿瘤血管生成研究述略[J].中国处方药,2004,29(8):30.
[132] Bergsland EK. Vascular endothelial growth factor as a therapeutic targetin cancer[J]. American Journal of Health System Pharmacy,2004,61(21):4-11.
[133]钱士辉.陈皮提取物体内抗肿瘤作用及其对癌细胞增殖周期的影响[J].中国中药杂志，2003,28(12):1167-1169.
[134]张会军,阎蕴力,张朱欣等.川芎嗪对人小细胞肺癌H446细胞的增殖抑制作用[J].肿瘤防治研究,2003,30(6):452.
[135]梁文杰,单保恩.中药拮抗P-糖蛋白介导的肿瘤多药耐药机制的研究进展[J].中草药,2004,34(4):466-469.
[136]秦善文,郑玉玲.抗肿瘤中药实验研究进展[J].河南中医，2005,25(2):76-78.
[137]何赛萍.中药抗肿瘤研究思路[J].浙江中医学院学报,2001,25(4):61-62.
[138]朱曰林,张一楚等.C-erbB2和EGFR在胃癌中表达的研究[J].中国肿瘤临床,1996,23(12):855-859.
[139]Hunter T.The epidermal growth factor receptor gene and its product[J].Nature,1984,311(5985):414-416.
[140]郝远瑞,丁贯一等.大肠癌EGF受体表达对细胞增殖的影响[J].华人消化杂志,1998,6(4):313-314.
[141]谭祥华,黄秀深等.青莪汤对Lewis肺癌小鼠MMP9、Ang-Ⅱ、EGF、微血管密度的影响[J].长春中医药大学学报,2010,1(8):14-15.
[142]唐广义,殷东风.肠积宁方促进大肠癌细胞株HT-29凋亡及干预相关基因bcl-2及bax表达的实验研究[J].现代肿瘤医学,2007,15(4):491-493.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |